Reply  by Krumsdorf, Ulrike et al.
We find the results of Krumsdorf et al. (1) to be of
interest in its detail of the natural course of unusual
device-related, large-burden thrombosus in the now un-
common setting of protamine use. We consider other
associative relationships, as well as the editorial recommen-
dations of Moore and Levi (2), to be unsubstantiated.
Clinicians should not base management decisions in pa-
tients with PFO and stroke on such anecdotal and highly
selected data. We await the results of ongoing and future
randomized clinical trials to address these concerns.
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Incidence and Clinical Course of Thrombus
Formation on Atrial Septal Defect
and Patent Foramen Ovale Closure Devices
Krumsdorf et al. (1) present impressive data concerning the
risk of thrombus formation on closure devices for atrial
septal defects (ASDs) and patent foramen ovale (PFO) in
1,000 consecutive patients.
The vast majority of these patients were treated in the
Bethanien-Hospital where we worked together with Dr.
Sievert from July 1995 until he left our institution in June
2003. Until October 27, 2000, we shared the scientific
database for all patients who had received an atrial septal
implant. Therefore, we would like to add some information
on two of our patients who were apparently included in the
series of Krumsdorf et al. (1).
One PFO patient with an Amplatzer (AGA Medical
Corp., Golden Valley, Minnesota) occluder developed
thrombus on the left atrial disk of the device, which was
detected by transesophageal echocardiography (TEE) five
weeks after implantation (implanted January 26, 2000; TEE
date March 1, 2000). With heparinization and anticoagu-
lation, the further course was uneventful.
Another PFO patient suffered two strokes 5.7 years after
implantation of a Buttoned device (Custom Medical De-
vices, Amarillo, Texas). The TEE revealed a 10  7-mm
thrombus on the left atrial disk of the occluder (implanta-
tion date March 4, 1996; TEE date November 16, 2001).
The thrombus resolved after heparinization and anticoagu-
lation, and the further clinical course was uneventful. The
latter event was published as a case report (2).
We believe that these data might be clinically relevant,
not only because thrombus formation may occur early after
implantation of an Amplatzer device, but more importantly,
even after more than five years following defect closure.
Therefore, all investigators involved in the field of interven-
tional ASD closure have the obligation to follow their (own)
patients for an unlimited period of time.
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REPLY
We greatly appreciate the comments and suggestions by
Drs. Landzberg and colleagues, Massimo and colleagues,
Jux and Bertram, and Schräder regarding our recent paper
(1).
First, we absolutely share the opinion of Landzberg and
colleagues that randomized trials are superior to nonran-
domized trials! Conversely, nonrandomized trials are better
than no trials at all! And before a randomized trial can be
initiated we have to have an idea about what we are looking
for and what the incidence of a specific event like thrombus
formation might be. Dr. Landzberg and his colleagues know
very well how difficult it is to conduct a randomized trial in
catheter closure of intracardiac defects. Although the first
transcatheter atrial septal defect (ASD) closure was per-
formed more than 25 years ago, until today no randomized
trial has ever been started.
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Regarding patent foramen ovale (PFO) closure, initial
experience in nonrandomized trials in their centers and in
our center provided the data to adequately plan and conduct
randomized trials that have just been initiated. Results will
probably not be available within the next three to five years.
We are sure that Dr. Landzberg and colleagues acknowl-
edge that this is the first study in which transesophageal
echocardiography (TEE) follow-up was performed in a
prospective way in a patient group large enough to detect
significant numbers of rare adverse events like thrombus
formation. Now we know that the incidence of thrombus
formation is low. With this information one might consider
randomized trials to investigate this issue further. However,
it is not very likely that the occurrence of thrombi on
different devices will ever be investigated in a randomized
trial. Their criticism regarding preprocedural assessment of
prothrombotic risks, intraobserver variability, interobserver
variability, and so forth is well taken, but this has to be
investigated in the next 1,000-patient study. Also, we totally
agree that it is very difficult to define sensitivity and
specificity of echocardiographically detected device-related
thrombosis because there is apparently no other technique
available to diagnose thrombus formation better than TEE.
So how can we determine sensitivity and specificity?
Dr. Massimo and colleagues underlined the role of
activated clotting time (ACT) during the procedure in their
experience. We did not monitor anticoagulation by the
ACT. In our patient population, we have no doubt that
during the procedure the ACT was within therapeutic range
because our standard dose of heparin was 20,000 U until
Patient #817 and 10,000 U after Patient #818. Initially this
was according to one of the study protocols. Later this high
dose of heparin was also used in clinical practice owing to
apparently good results. Nineteen of 20 patients with
thrombus formation had received 20,000 U of heparin
during the procedure. More important may be the fact that
the first 817 patients (and accordingly 19 of 20 thrombus
patients) received protamine at the end of the procedure to
allow early sheath removal.
Dr. Massimo and colleagues also speculated that throm-
bus formation may have occurred immediately after the
procedure. It is well known that, in adults, atrial thrombus
formation after device closure can neither be diagnosed nor
excluded with TEE. Recently, similar incidences of throm-
bus formation on closure devices have been reported with-
out use of protamine (2). Furthermore, it is a fact that
protamine is used routinely to reverse the anticoagulant
effect of heparin following cardiac surgery, including valve
replacement and ASD patch closure, other vascular proce-
dures, and hemodialysis, apparently without causing throm-
boembolic complications (3–6). Protamine acts as a heparin
antagonist, but it does not have any thrombogenic potential.
Conversely, excessive protamine administration or pro-
tamine administration in the absence of heparin has an
anticoagulant effect and can result in a “paradoxical”
bleeding diathesis (7,8). Protamine given before sheath
removal was not a significant risk factor for thrombus
formation in our patients, but this may be due to the
small numbers of patients treated without protamine. In
the last three decades there have been several prospective
studies with cohorts ranging from 50 to 429 patients
(9 –14) and which tested the approach of reversing
anticoagulation by protamine administration after percu-
taneous coronary intervention. Shorter compression
times, lower incidence of bleedings, rapid mobilization,
and significant reduction in the number of in-hospital
days had been the main advantages. Reversal of antico-
agulation by protamine even after stent implantation did
not predispose to thrombotic complications (11–14).
We agree with Dr. Massimo and colleagues that a
prolonged antiplatelet therapy may help to prevent late
thrombus formation. One thrombus was detected five years
after implantation. However, we do not know at what time
these late thrombi develop. This event is so rare that it is an
open question whether a prolonged (6 months) antiplate-
let therapy that has its own risks is justified.
Of course, all 593 PFO patients had an embolic event
prior to the procedure. Otherwise a PFO closure would not
have been indicated. On average, our 593 patients had 1.2
embolic events before the procedure.
We agree with Drs. Jux and Bertram that a routine
follow-up by TEE should be performed for all intracardiac
devices. As described on page 304 in our study (1), throm-
bus formation also occurred on an Amplatzer (AGA Med-
ical Corp., Golden Valley, Minnesota) device. Age was not
a risk factor for thrombus formation in our adult patient
population, but of course this may be different if children are
taken into consideration. We are aware of the fact that in
some other series the incidence of thrombus formation, even
with the CardioSEAL/STARflex (NMT Medical, Boston,
Massachusetts) and the PFO-Star (Applied Biometrics Inc.,
Barnsville, Minnesota), was lower than in our patient
population. In some of these series, children were included
(obviously with a lower risk of thrombus formation); in
some others it was not clear in how many patients and how
long after implantation a TEE follow-up was actually
performed (15–17).
Regarding the comments of Dr. Schräder, the thrombus
on the Amplatzer device did not occur after four weeks but
six months after implantation as described in our study on
page 304 (1). Regarding the thrombus detected by Gaul et
al. (18), 5.7 years after implantation of a Sideris occluder in
our institution: this confirms our experience that late throm-
bus formation may occur. We are happy to hear that Dr.
Schräder now shares our opinion that life-long follow-up
after device closure is mandatory.
As Moore and Levi (19) noted in their editorial, our report
offers reasonable assurance that the incidence of thrombi and
related embolic events is low enough to justify continued use
for ASD and PFO closure and that thrombus formation
usually resolves under appropriate anticoagulation therapy. We
would like to emphasize that, for the most part, PFO closure
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with a device is a safe and simple procedure. Every device offers
some advantage over others, and indeed there is no “perfect”
device on the market today. Like any new therapy, optimizing
the treatment requires a certain degree of learning and risk. It
is also important to note that other complications are associ-
ated with different devices not addressed in our report. There-
fore, placing judgment and device selection on one attribute is
not appropriate.
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